Prolonged bisphosphonate release after treatment in children
SE Papapoulos, SCLM Cremers - New England Journal of …, 2007 - Mass Medical Soc
SE Papapoulos, SCLM Cremers
New England Journal of Medicine, 2007•Mass Medical SocTo the Editor: Bisphosphonates are widely used in the management of osteoporosis. They
are cleared rapidly from the circulation, with about half the administered dose taken up by
the skeleton and the rest excreted unmetabolized by the kidneys. 1 At the bone surface,
bisphosphonates suppress bone resorption and are embedded in bone. The embedded
bisphosphonate is released slowly from bone, presumably after the resumption of bone
remodeling at previously exposed sites. A terminal half-life of 10 years has been estimated …
are cleared rapidly from the circulation, with about half the administered dose taken up by
the skeleton and the rest excreted unmetabolized by the kidneys. 1 At the bone surface,
bisphosphonates suppress bone resorption and are embedded in bone. The embedded
bisphosphonate is released slowly from bone, presumably after the resumption of bone
remodeling at previously exposed sites. A terminal half-life of 10 years has been estimated …
To the Editor: Bisphosphonates are widely used in the management of osteoporosis. They are cleared rapidly from the circulation, with about half the administered dose taken up by the skeleton and the rest excreted unmetabolized by the kidneys.1 At the bone surface, bisphosphonates suppress bone resorption and are embedded in bone. The embedded bisphosphonate is released slowly from bone, presumably after the resumption of bone remodeling at previously exposed sites.
A terminal half-life of 10 years has been estimated for alendronate in the longest pharmacokinetic study in humans, up to 1.5 years, after intravenous administration. There is no direct evidence . . .
The New England Journal Of Medicine